Welcome to our dedicated page for Neurocrine Biosciences SEC filings (Ticker: NBIX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Neurocrine Biosciences Inc. filings document the regulatory record of a commercial biopharmaceutical company developing and selling treatments for neurological, psychiatric, endocrine and immunological disorders. Its 8-K reports cover operating and financial results, product-sales disclosures, clinical or regulatory updates, material agreements, capital-structure matters and executive or employment-related governance events.
Proxy filings describe board matters, shareholder voting items, executive compensation, equity awards and pay-versus-performance disclosures. The filing record also includes formal disclosures related to INGREZZA, CRENESSITY and the company's pipeline, as well as risk, governance and transaction-related disclosure categories relevant to its public-company status.
Neurocrine Biosciences reported very strong first-quarter 2026 results, with total revenues of $814.5 million, up 42% from the prior year, driven by growth in key neurology and endocrine drugs.
Net product sales reached $811.0 million, a 44% increase year-over-year. INGREZZA delivered $656.9 million in sales, up 20%, while newly launched CRENESSITY generated $153.3 million. GAAP net income jumped to $197.9 million, with diluted EPS of $1.91, and Non-GAAP EPS was $1.94.
The company entered a definitive agreement to acquire Soleno Therapeutics for an equity value of $2.9 billion, adding VYKAT XR for hyperphagia in Prader-Willi syndrome, and reaffirmed 2026 INGREZZA net sales guidance of $2.7–$2.8 billion. Cash, cash equivalents, and marketable securities totaled about $2.65 billion as of March 31, 2026.
Neurocrine Biosciences reported very strong first-quarter 2026 results, with total revenues of $814.5 million, up 42% from the prior year, driven by growth in key neurology and endocrine drugs.
Net product sales reached $811.0 million, a 44% increase year-over-year. INGREZZA delivered $656.9 million in sales, up 20%, while newly launched CRENESSITY generated $153.3 million. GAAP net income jumped to $197.9 million, with diluted EPS of $1.91, and Non-GAAP EPS was $1.94.
The company entered a definitive agreement to acquire Soleno Therapeutics for an equity value of $2.9 billion, adding VYKAT XR for hyperphagia in Prader-Willi syndrome, and reaffirmed 2026 INGREZZA net sales guidance of $2.7–$2.8 billion. Cash, cash equivalents, and marketable securities totaled about $2.65 billion as of March 31, 2026.
Vanguard Capital Management filed a Schedule 13G reporting beneficial ownership of 5,257,941 shares of Neurocrine Biosciences common stock, representing 5.23% of the class as of 03/31/2026. The filing states Vanguard Capital Management LLC and specified Vanguard affiliates exercise dispositive power over these shares and that holdings include securities held for Vanguard funds and managed clients. The statement is signed by Ashley Grim, Head of Global Fund Administration, on 04/30/2026.
Neurocrine Biosciences and its subsidiary Sigma Merger Sub have amended their tender offer for Soleno Therapeutics, offering $53.00 per share in cash for all outstanding common shares. This Amendment No. 2 supplements the Schedule TO and adds a Soleno Employee FAQ as an exhibit, with other offer terms remaining as filed.
Neurocrine Biosciences and its subsidiary Sigma Merger Sub have amended their tender offer for Soleno Therapeutics, offering $53.00 per share in cash for all outstanding common shares. This Amendment No. 2 supplements the Schedule TO and adds a Soleno Employee FAQ as an exhibit, with other offer terms remaining as filed.
Neurocrine Biosciences has amended its Schedule TO to confirm the tender offer by its subsidiary Sigma Merger Sub to acquire all outstanding Soleno Therapeutics common shares for $53.00 per share, payable in cash. The filing states the HSR Act waiting period expired as of April 27, 2026, satisfying the Regulatory Condition to the Offer; the Offer remains subject to the remaining conditions set forth in the Offer to Purchase.
Neurocrine Biosciences has amended its Schedule TO to confirm the tender offer by its subsidiary Sigma Merger Sub to acquire all outstanding Soleno Therapeutics common shares for $53.00 per share, payable in cash. The filing states the HSR Act waiting period expired as of April 27, 2026, satisfying the Regulatory Condition to the Offer; the Offer remains subject to the remaining conditions set forth in the Offer to Purchase.
Neurocrine Biosciences, Inc. is conducting a cash tender offer to acquire Soleno Therapeutics, Inc. at $53.00 per share under the Offer to Purchase dated April 20, 2026. The offer, made by Neurocrine's wholly owned subsidiary Sigma Merger Sub, Inc., covers all outstanding Soleno common shares.
The Offer to Purchase, Letter of Transmittal and related transaction agreements (including an Agreement and Plan of Merger dated April 5, 2026) are attached as exhibits and incorporated by reference. The offer is payable in cash, subject to customary terms, conditions and any applicable withholding taxes; the filing states the Offer is not subject to a financing condition.
Neurocrine Biosciences, Inc. is conducting a cash tender offer to acquire Soleno Therapeutics, Inc. at $53.00 per share under the Offer to Purchase dated April 20, 2026. The offer, made by Neurocrine's wholly owned subsidiary Sigma Merger Sub, Inc., covers all outstanding Soleno common shares.
The Offer to Purchase, Letter of Transmittal and related transaction agreements (including an Agreement and Plan of Merger dated April 5, 2026) are attached as exhibits and incorporated by reference. The offer is payable in cash, subject to customary terms, conditions and any applicable withholding taxes; the filing states the Offer is not subject to a financing condition.
Neurocrine Biosciences, Inc. will hold its 2026 annual stockholders’ meeting on May 27, 2026 at 10:30 a.m. in San Diego. Stockholders of record as of March 31, 2026, when 100,581,991 common shares were outstanding, may vote.
They are being asked to elect three Class III directors, cast an advisory vote on executive compensation, and approve an amendment to the 2025 Equity Incentive Plan that would increase shares reserved for issuance by 4,000,000. Investors will also vote on ratifying Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2026. The Board recommends voting “for” all four proposals and highlights a range of governance practices, including proxy access, a clawback policy, and a classified board structure.
Neurocrine Biosciences has announced a planned tender offer by its wholly owned subsidiary, Sigma Merger Sub, for all outstanding shares of Soleno Therapeutics, Inc., pursuant to an Agreement and Plan of Merger dated April 5, 2026. The communication states the tender offer has not commenced and that formal tender offer materials and Soleno’s solicitation/recommendation on Schedule 14D-9 will be filed with the SEC when the offer begins. Forward-looking statements and customary closing conditions are included; timing, price, and the number of shares to be acquired are not provided in the excerpt.
Neurocrine Biosciences has announced a planned tender offer by its wholly owned subsidiary, Sigma Merger Sub, for all outstanding shares of Soleno Therapeutics, Inc., pursuant to an Agreement and Plan of Merger dated April 5, 2026. The communication states the tender offer has not commenced and that formal tender offer materials and Soleno’s solicitation/recommendation on Schedule 14D-9 will be filed with the SEC when the offer begins. Forward-looking statements and customary closing conditions are included; timing, price, and the number of shares to be acquired are not provided in the excerpt.
Neurocrine Biosciences and its acquisition subsidiary, Sigma Merger Sub, intend to launch a tender offer for all outstanding shares of Soleno Therapeutics, Inc. The planned tender offer is to be made pursuant to an Agreement and Plan of Merger, dated April 5, 2026. The communication describes procedural next steps: a Schedule TO tender offer statement to be filed by Neurocrine and its acquisition subsidiary and a Schedule 14D-9 solicitation/recommendation statement to be filed by Soleno; the offer has not commenced.
The statement includes customary forward-looking disclaimers about timing, closing conditions, potential competing proposals, regulatory uncertainty, integration risks, and other standard transaction risks.
Neurocrine Biosciences and its acquisition subsidiary, Sigma Merger Sub, intend to launch a tender offer for all outstanding shares of Soleno Therapeutics, Inc. The planned tender offer is to be made pursuant to an Agreement and Plan of Merger, dated April 5, 2026. The communication describes procedural next steps: a Schedule TO tender offer statement to be filed by Neurocrine and its acquisition subsidiary and a Schedule 14D-9 solicitation/recommendation statement to be filed by Soleno; the offer has not commenced.
The statement includes customary forward-looking disclaimers about timing, closing conditions, potential competing proposals, regulatory uncertainty, integration risks, and other standard transaction risks.
Neurocrine Biosciences entered into an Agreement and Plan of Merger to acquire Soleno Therapeutics via a cash tender offer at $53.00 per share. Neurocrine will commence the offer within ten business days and keep it open for twenty business days, subject to customary conditions, antitrust clearances and possible extensions.
The agreement contemplates a subsequent short-form merger under Section 251(h) of the DGCL; certain Soleno equity awards, RSUs and warrants will be cashed out at the Offer Price or treated per their terms. The merger agreement includes a $95,250,000 termination fee and a $141,500,000 reverse termination fee. Supporting stockholders hold approximately 1.01% of Soleno shares.
Neurocrine Biosciences entered into an Agreement and Plan of Merger to acquire Soleno Therapeutics via a cash tender offer at $53.00 per share. Neurocrine will commence the offer within ten business days and keep it open for twenty business days, subject to customary conditions, antitrust clearances and possible extensions.
The agreement contemplates a subsequent short-form merger under Section 251(h) of the DGCL; certain Soleno equity awards, RSUs and warrants will be cashed out at the Offer Price or treated per their terms. The merger agreement includes a $95,250,000 termination fee and a $141,500,000 reverse termination fee. Supporting stockholders hold approximately 1.01% of Soleno shares.